title: Cutaneous sarcoidosis developing after treatment with pegylated interferon and ribavirin: a new case and review of the literature.
abstract: Sarcoidosis is a multisystem granulomatous disease that affects multiple organs in adults between 20 and 50 years old. Interferon alpha (IFN-α) is an immunomodulator that has been used in a wide range of diseases, including hepatitis C virus infection, multiple sclerosis, and other types of neoplasias, including leukemia, lymphoma, Kaposi's sarcoma, and melanoma. Standard IFN-α-induced sarcoidosis has been reported, but there are few reports of cutaneous sarcoidosis with pegylated IFN-α therapy. We present a new case of cutaneous sarcoidosis after treatment with pegylated IFN, and a review of the literature.
authors.affiliation: Department of Dermatology, Hospital Clínico Universitario de Valencia, Valencia, Spain. veronica_17@live.com
authors.forename: Verónica
authors.initials: V
authors.lastname: López
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Molina
authors.forename: Carlos
authors.initials: C
authors.lastname: Monteagudo
authors.forename: Esperanza
authors.initials: E
authors.lastname: Jordá
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects*; D012507:Sarcoidosis / Q000139:chemically induced*; D012871:Skin Diseases / Q000139:chemically induced*
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a